Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Glucagonoma
ADR ID BADD_A11222
ADR Hierarchy
05      Endocrine disorders
05.08      Neoplastic and ectopic endocrinopathies
05.08.01      Endocrine neoplasms NEC
05.08.01.022      Glucagonoma
07      Gastrointestinal disorders
07.21      Malignant and unspecified neoplasms gastrointestinal NEC
07.21.09      Pancreatic neoplasms
07.21.09.013      Glucagonoma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.24      Endocrine neoplasms malignant and unspecified
16.24.02      Islet cell neoplasms and APUDoma NEC
16.24.02.008      Glucagonoma
Description An almost always malignant GLUCAGON-secreting tumor derived from the PANCREATIC ALPHA CELLS. It is characterized by a distinctive migratory ERYTHEMA; WEIGHT LOSS; STOMATITIS; GLOSSITIS; DIABETES MELLITUS; hypoaminoacidemia; and normochromic normocytic ANEMIA. [MeSH]
MedDRA Code 10018404
MeSH ID D005935
ADR Severity Grade (FAERS) Not Available
ADR Severity Grade (CTCAE) Not Available
Synonym
Glucagonoma | Glucagonomas | alpha-Cell Tumor | Tumor, alpha-Cell | Tumors, alpha-Cell | alpha Cell Tumor | alpha-Cell Tumors | Glucagonoma Syndrome | Glucagonoma Syndromes | Syndrome, Glucagonoma | Syndromes, Glucagonoma | Adenoma, alpha-Cell | Adenoma, alpha Cell | Adenomas, alpha-Cell | alpha-Cell Adenoma | alpha-Cell Adenomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02412Octreotide--
The 1th Page    1    Total 1 Pages